MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329827 | Name: Mirodenafil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mirodenafil, also known as SK3530, belongs to the drug class PDE5 inhibitors, which includes avanafil, sildenafil, tadalafil, udenafil, and vardenafil, and is the first-line treatment for erectile dysfunction. Developed by SK Chemicals Life Science, mirodenafil is marketed in Korea under the trade name Mvix, offered both as tablets (50 mg and 100 mg) and as orally dissolving film (50 mg). Several clinical trials were conducted, but mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.

Chemical Structure

Mirodenafil
Mirodenafil
CAS#862189-95-5

Theoretical Analysis

MedKoo Cat#: 329827

Name: Mirodenafil

CAS#: 862189-95-5

Chemical Formula: C26H37N5O5S

Exact Mass: 531.2515

Molecular Weight: 531.67

Elemental Analysis: C, 58.74; H, 7.01; N, 13.17; O, 15.05; S, 6.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SK3530; SK-3530; SK 3530; Mirodenafil, trade name Mvix.
IUPAC/Chemical Name
5-Ethyl-3,5-dihydro-2-[5-([4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl)-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one
InChi Key
MIJFNYMSCFYZNY-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)
SMILES Code
O=C1C(N(CC)C=C2CCC)=C2N=C(C3=CC(S(=O)(N4CCN(CCO)CC4)=O)=CC=C3OCCC)N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 531.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cho MC, Paick JS. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. Ther Adv Urol. 2016 Apr;8(2):100-17. doi: 10.1177/1756287215625408. Epub 2016 Jan 19. Review. PubMed PMID: 27034723; PubMed Central PMCID: PMC4772359. 2: Shim JS, Bae JH. Drug Concentration in Rat Plasma, Bladder, and Prostate After Mirodenafil Administration in a Chronic Pelvic Ischemia Model. Urology. 2016 May;91:244.e1-5. doi: 10.1016/j.urology.2016.02.017. Epub 2016 Feb 23. PubMed PMID: 26919966. 3: Ventimiglia E, Capogrosso P, Montorsi F, Salonia A. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf. 2016;15(2):141-52. doi: 10.1517/14740338.2016.1131818. Epub 2016 Jan 9. Review. PubMed PMID: 26752541. 4: Choi H, Bae JH, Shim JS, Park JY, Moon du G, Lee JG. Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats. Int Neurourol J. 2015 Mar;19(1):19-26. doi: 10.5213/inj.2015.19.1.19. Epub 2015 Mar 26. PubMed PMID: 25833477; PubMed Central PMCID: PMC4386487. 5: Peak TC, Yafi FA, Sangkum P, Hellstrom WJ. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015 Jun;20(2):263-75. doi: 10.1517/14728214.2015.1021682. Epub 2015 Mar 5. Review. PubMed PMID: 25740087. 6: Kong do H, Yun CJ, Park HJ, Park NC. The efficacy of mirodenafil for chronic prostatitis/chronic pelvic pain syndrome in middle-aged males. World J Mens Health. 2014 Dec;32(3):145-50. doi: 10.5534/wjmh.2014.32.3.145. Epub 2014 Dec 29. PubMed PMID: 25606563; PubMed Central PMCID: PMC4298817. 7: Lee S, Choi B, Kim J, In S, Baeck S, Oh SM, Chung KH. An LC-MS/MS method for the determination of five erectile dysfunction drugs and their selected metabolites in hair. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:1-10. doi: 10.1016/j.jchromb.2014.11.024. Epub 2014 Dec 5. PubMed PMID: 25531864. 8: Li J, Shi Q, Wei Q, Han P. Re: Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male. 2015 Jun;18(2):71. doi: 10.3109/13685538.2014.954994. Epub 2014 Aug 27. PubMed PMID: 25162329. 9: Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014 Apr;32(1):18-27. doi: 10.5534/wjmh.2014.32.1.18. Epub 2014 Apr 25. Review. PubMed PMID: 24872948; PubMed Central PMCID: PMC4026230. 10: Lee DS, Choe HS, Kim SW, Jung KU, Lee SJ. Impact of the change in urinary and sexual function on health-related quality of life after once daily low-dose mirodenafil treatment in patients with organic erectile dysfunction. Urol Int. 2014;93(1):84-91. doi: 10.1159/000355360. Epub 2014 Jan 23. PubMed PMID: 24457224. 11: Du W, Li J, Fan N, Shang P, Wang Z, Ding H. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male. 2014 Jun;17(2):107-11. doi: 10.3109/13685538.2013.858114. Epub 2013 Nov 12. PubMed PMID: 24219508. 12: Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, Cho JS, Lee SK, Yang DY. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med. 2013 Nov;10(11):2832-41. doi: 10.1111/jsm.12287. Epub 2013 Aug 12. PubMed PMID: 23937271. 13: Kang JY, Kim EK, Kim KM. Effects of mirodenafil, a phosphodiesterase-5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model: physiological and immunohistochemical aspects. Korean J Urol. 2013 May;54(5):339-44. doi: 10.4111/kju.2013.54.5.339. Epub 2013 May 14. PubMed PMID: 23700501; PubMed Central PMCID: PMC3659229. 14: Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44. doi: 10.1517/14656566.2013.799665. Epub 2013 May 16. Review. PubMed PMID: 23675780. 15: Cho DY, Bae SH, Shon JH, Bae SK. High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil. J Sep Sci. 2013 Mar;36(5):840-8. doi: 10.1002/jssc.201200919. Epub 2013 Feb 6. PubMed PMID: 23390072. 16: Kedia GT, Uckert S, Assadi-Pour F, Kuczyk MA, Albrecht K. Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. Ther Adv Urol. 2013 Feb;5(1):35-41. doi: 10.1177/1756287212466282. PubMed PMID: 23372609; PubMed Central PMCID: PMC3547533. 17: Lee S, Kang SY, Ji D, Baeck S, Lee S, Oh SM, Chung KH. Quantitative LC-MS/MS method in urine for the detection of drugs used to reverse the effects of chemical castration. Anal Bioanal Chem. 2013 Apr;405(10):3185-94. doi: 10.1007/s00216-013-6769-5. Epub 2013 Feb 1. PubMed PMID: 23371534. 18: Bang WJ, Oh CY, Yoo C, Cho JS, Yang DY, Lee DH, Lee SH, Chung BH. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study. Int J Impot Res. 2013 Jul-Aug;25(4):149-54. doi: 10.1038/ijir.2012.44. Epub 2013 Jan 10. PubMed PMID: 23303333. 19: Gacci M. Editorial comment. J Urol. 2013 Mar;189(3):1013. doi: 10.1016/j.juro.2012.08.276. Epub 2012 Dec 11. PubMed PMID: 23246205. 20: Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013 Jan;29(1):1-12. doi: 10.1185/03007995.2012.747952. Epub 2012 Nov 30. Review. PubMed PMID: 23136913.

View History

Mirisetron Maleate

Mirisetron Maleate